Search research articles
Contact Us
Filters
Showing results (111-120 of 159) with videos related to
Page
of 16
Sort By:
International Journal of Radiation Oncology, Biology, Physics
|
June 21, 2020
Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK)
Shankar Siva, Rohann J M Correa, Andrew Warner, et al.
Cancer Medicine
|
September 12, 2025
Associations of the Colon Tissue Microbiome and Circulating Bile Acids With Colorectal Adenoma Among Average-Risk Women
Doratha A Byrd, Maria F Gomez, Stephanie R Hogue, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2015
Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis
George Rodrigues, Cary Oberije, Suresh Senan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 17, 2013
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis
David A Palma, Suresh Senan, Cary Oberije, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 15, 2022
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial
Matthew Van Oirschot, Alanah Bergman, Wilko F A R Verbakel, et al.
Radiation Oncology (London, England)
|
January 29, 2017
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
David A Palma, Timothy K Nguyen, Keith Kwan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 13, 2016
Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Andrew Warner, Max Dahele, Bo Hu, et al.
Thoracic Cancer
|
May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial
Richard A Malthaner, Edward Yu, Michael Sanatani, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 7, 2025
Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial
Sondos Zayed, Pencilla Lang, Nancy Read, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
X Melody Qu, Yujie Chen, Gregory S Zaric, et al.
Page
of 16
Search research articles
Search
Showing results (111-120 of 159) with videos related to
Sort By:
Page
of 16
International Journal of Radiation Oncology, Biology, Physics
|
June 21, 2020
Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK)
Shankar Siva, Rohann J M Correa, Andrew Warner, et al.
Cancer Medicine
|
September 12, 2025
Associations of the Colon Tissue Microbiome and Circulating Bile Acids With Colorectal Adenoma Among Average-Risk Women
Doratha A Byrd, Maria F Gomez, Stephanie R Hogue, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 4, 2015
Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis
George Rodrigues, Cary Oberije, Suresh Senan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
September 17, 2013
Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis
David A Palma, Suresh Senan, Cary Oberije, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 15, 2022
Determining Planning Priorities for SABR for Oligometastatic Disease: A Secondary Analysis of the SABR-COMET Phase II Randomized Trial
Matthew Van Oirschot, Alanah Bergman, Wilko F A R Verbakel, et al.
Radiation Oncology (London, England)
|
January 29, 2017
Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)
David A Palma, Timothy K Nguyen, Keith Kwan, et al.
International Journal of Radiation Oncology, Biology, Physics
|
February 13, 2016
Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Andrew Warner, Max Dahele, Bo Hu, et al.
Thoracic Cancer
|
May 25, 2022
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial
Richard A Malthaner, Edward Yu, Michael Sanatani, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 7, 2025
Opioid therapy vs. Multimodal analgesia in head and neck cancer (OPTIMAL-HN): Results of a randomized clinical trial
Sondos Zayed, Pencilla Lang, Nancy Read, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 14, 2020
Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
X Melody Qu, Yujie Chen, Gregory S Zaric, et al.
Page
of 16